Continuing trastuzumab beyond progression

Journal of Clinical Oncology

Volumn 27, Issue 12, 2009, Pages 1935-1937

  Jahanzeb, Mohammad ^a,b  

^a UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^b Aptium Oncology

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; LAPATINIB; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SOMATOMEDIN C RECEPTOR; TANESPIMYCIN; TENSIN; TRASTUZUMAB;

ANTIANGIOGENIC THERAPY; BLOOD BRAIN BARRIER; BRAIN METASTASIS; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER REGISTRY; CANCER SURVIVAL; CLINICAL DECISION MAKING; CLINICAL TRIAL; DIARRHEA; DISEASE FREE SURVIVAL; DRUG ABSORPTION; DRUG ERUPTION; DRUG SAFETY; EDITORIAL; HUMAN; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; STRUCTURAL HOMOLOGY; THERAPY EFFECT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WORLD HEALTH ORGANIZATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; RECEPTOR, ERBB-2;

EID: 65349158268     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.20.8215     Document Type: Editorial

References (19)

1. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
2. Tripathy D, Salmon DJ, Cobleigh M,et al: Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 22:1063-1070, 2004
3. Reference deleted
4. Gelmon KA, Mackey J, Verma S, et al: Use of trastuzumab beyond disease progression: Observations from a retrospective review of case histories. Clin Breast Cancer 5:52-58, 2004; discussion 59-62
5. Jackisch C, Eustermann H, Schoenegg W, et al: Clinical use of trastuzumab (Herceptin) in metastatic breast cancer (MBC) in Germany from 2001 to 2006. Presented at San Antonio Breast Cancer Symposium, San Antonio, TX, December 13-16, 2007 (suppl; abstr 4059)
6. García-Sáenz JA, Martin M, Puente J, et al: Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer. Clin Breast Cancer 6:325-329, 2005
7. Stemmler HJ, Kahlert S, Siekiera W, et al: Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC). Onkologie 28:5826, 2005
8. Geyer CE, Forster J, Lindquist D, et at: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733-2743, 2006
9. von Minckwitz G, du Bois A, Schmidt M, et al: Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: A German Breast Group 26/Breast International Group 03-05 Study. J Clin Oncol 27:1999-2006, 2009
10. O'Shaughnessy J, Blackwell KL, Burstein H, et al: A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2 + metastatic breast cancer progressing on trastuzumab therapy. J Clin Oncol 26:44s, 2008 (suppl; abstr 1015) 10a. Migliaccio I, Gutierrez MC, Wu M-F, et al: P13 Kinase activation and response to trastuzumab or lapatinib in HER-2 overexpressing locally advanced breast cancer (LABC). Cancer Res 69:71s, 2009 (suppl; abstr 34)
11. ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D. http://www.clinicaltrials.gov/ct2/show/NCT00490139
12. National Comprehensive Cancer Network: Breast Cancer Guidelines http://www.nccn.org/professionals/physician-gls/PDF/breast.pdf
13. Lin NU, Dieras V, Paul D, et al: EGF105084, a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (H) based systemic therapy and cranial radiotherapy (RT). J Clin Oncol 25:35s, 2007 (suppl; abstr 1012)
14. Gelmon KA, Fumoleau P, Verma S, et al: Results of a phase II trial of trastuzumab (H) and Pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapy. J Clin Oncol 26:47s, 2008 (suppl; abstr 1026)
15. Holden SN, Beeram M, Krop IE, et al: A phase I study of weekly dosing of trastuzumab-DM1 (T-DM1) in patients (pts) with advanced HER2+ breast cancer (BC). J Clin Oncol 26:48s, 2008 (suppl; abstr 1029)
16. Beeram M, Burris HA III, Modi S, et al: A phase I study of trastuzumab- DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with advanced HER2+ breast cancer (BC). J Clin Oncol 26:48s, 2008 (suppl; abstr 1028)
17. Modi S, Sugarman S, Stopeck A, et al: Phase II trial of the Hsp90 nhibitor tanespimycin (Tan) + trastuzumab (T) in patients (pts) with HER2- positive metastatic breast cancer (MBC). J Clin Oncol 26:47s, 2008 (suppl; abstr 1027)
18. Andre F, Campone M, Hurvitz SA, et al: Multicenter phase I clinical trial of daily and weekly RAD001 in combination with weekly paclitaxel and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab. J Clin Oncol 26:41s, 2008 (suppl: abstr 1003)
19. Pegram M, Yeon C, Durna LN, et al: San Antonio Breast Cancer Symposium. Breast Cancer Res Treat 100:2006 (suppl; abstr 301)